4,214 AbbVie Inc. $ABBV Shares Purchased by SVB Wealth LLC

SVB Wealth LLC raised its stake in shares of AbbVie Inc. (NYSE:ABBV) by 7.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,646 shares of the company’s stock after buying an additional 4,214 shares during the period. AbbVie accounts for approximately 1.0% of SVB Wealth LLC’s portfolio, making the stock its 23rd biggest holding. SVB Wealth LLC’s holdings in AbbVie were worth $14,856,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. State Street Corp boosted its stake in shares of AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after acquiring an additional 1,379,232 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after acquiring an additional 106,091 shares in the last quarter. Legal & General Group Plc bought a new position in shares of AbbVie in the 2nd quarter valued at approximately $2,905,952,000. Deutsche Bank AG raised its stake in shares of AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after acquiring an additional 1,241,587 shares in the last quarter. Finally, Amundi raised its stake in shares of AbbVie by 2.4% in the 1st quarter. Amundi now owns 10,698,095 shares of the company’s stock valued at $2,326,728,000 after acquiring an additional 247,689 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Down 0.1%

Shares of NYSE:ABBV opened at $294.75 on Friday. The company has a market cap of $521.01 billion, a price-to-earnings ratio of 50.73, a PEG ratio of 1.34 and a beta of 0.20. The business has a 50 day moving average price of $274.82 and a 200 day moving average price of $240.55. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $302.93.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The company had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same period in the previous year, the business posted $1.86 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Analysts anticipate that AbbVie Inc. will post 13.98 EPS for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be paid a $1.82 dividend. The ex-dividend date is Friday, January 15th. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. AbbVie’s dividend payout ratio is 119.10%.

Recent AbbVie Headlines

These are some of the ABBV headlines that stood out recently:

• Positive Sentiment: AbbVie’s immunology sales rose 16.6% in the third quarter, with Skyrizi and Rinvoq growth more than offsetting Humira’s decline. The performance has supported higher 2026 sales expectations and strengthens the case that newer drugs can sustain growth. How Did AbbVie’s Immunology Franchise Fare in Q3?
• Neutral Sentiment: AbbVie’s licensing agreement with Nxera Pharma for an inflammatory bowel disease program adds a potential pipeline opportunity, but requires AbbVie to make an upfront payment and could involve substantial milestone payments. The deal’s longer-term value depends on development and commercial success. AbbVie Deal Altering the Investment Case for Nxera Pharma?
• Negative Sentiment: Executive Vice President Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. Insider sales can weigh on sentiment, though the filing does not explain the reason for the transaction. SEC Form 4 filing

Insider Transactions at AbbVie

In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of the stock in a transaction on Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the sale, the executive vice president directly owned 83,171 shares of the company’s stock, valued at $24,419,005.60. This represents a 32.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Scotiabank upped their target price on AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. Canaccord Genuity Group increased their price target on AbbVie from $290.00 to $338.00 and gave the company a “buy” rating in a report on Monday, November 2nd. Oppenheimer lifted their price target on shares of AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. HSBC boosted their price objective on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Finally, Bank of America reaffirmed a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $297.46.

AbbVie Profile

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.